Advances in Radiotherapy for Breast Cancer

Upadhyay, Rituraj; Bazan, Jose G.

doi:10.1016/j.soc.2023.03.002

Cited by 5 publications

(3 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, studies involving proton and carbon-ion irradiations have demonstrated their advantages in protecting surrounding organs such as the heart and lungs and minimizing low-dose area. However, initial studies with proton therapy raised concerns about poor cosmetic outcomes (56). While technological advancements in proton therapy have seemingly addressed this issue by increasing the number of radiation fields in treatment plans, excellent dosimetric results can already be achieved with techniques like DIBH and prone positioning.…”

Section: Technological Advancesmentioning

confidence: 99%

New Approaches in Breast Cancer Radiotherapy

Demircan,

Bese

2024

EJBH

View full text Add to dashboard Cite

Breast cancer is globally the most prevalent cancer type and has a favorable prognosis with a multi-modality approach. •Radiotherapy plays a crucial role in the adjuvant setting, and its benefit to local control and survival has been demonstrated by numerous randomized trials and meta-analyses with large datasets.• Recently, most efforts in breast cancer therapy have focused on better understanding the biology and genetics of tumors and de-intensifying treatment accordingly.• Contemporary studies aim to omit radiotherapy in low-risk patients. On the other hand, with advancements in technology and effective utilization of hypofractionation, evolved radiotherapy emerges as a more feasible option by minimizing radiation-related long-term toxicities and reducing its burden on the national healthcare system.

show abstract

Section: Technological Advancesmentioning

confidence: 99%

New Approaches in Breast Cancer Radiotherapy

Demircan,

Bese

2024

EJBH

View full text Add to dashboard Cite

show abstract

“…Radiation therapy plays a pivotal role in the multimodal approach to breast cancer management, including early-stage, locally advanced, and metastatic breast cancers 183 . After breast-conserving surgery, administering radiotherapy to the preserved breast significantly reduces the recurrence rate of the disease and lowers the breast cancer mortality rate by approximately one-sixth 184 .…”

Section: The Role Of Mscs In the Treatment Of Breast Cancermentioning

confidence: 99%

The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment

Zhang

2023

Cell Transplant

View full text Add to dashboard Cite

The role of mesenchymal stem cells (MSCs) in the breast tumor microenvironment (TME) is significant and multifaceted. MSCs are recruited to breast tumor sites through molecular signals released by tumor sites. Once in the TME, MSCs undergo polarization and interact with various cell populations, including immune cells, cancer-associated fibroblasts (CAFs), cancer stem cells (CSCs), and breast cancer cells. In most cases, MSCs play roles in breast cancer therapeutic resistance, but there is also evidence that indicates their abilities to sensitize cancer cells to chemotherapy and radiotherapy. MSCs possess inherent regenerative and homing properties, making them attractive candidates for cell-based therapies. Therefore, MSCs can be engineered to express therapeutic molecules or deliver anti-cancer agents directly to tumor sites. Unraveling the intricate relationship between MSCs and the breast TME has the potential to uncover novel therapeutic targets and advance our understanding of breast cancer biology.

show abstract

“…Also, radiotherapy is an important component of breast cancer management, both locally and at the metastasis site(s). Breast conservation with lumpectomy followed by whole or partial breast radiation is the current standard of care for early breast cancer cases and improves the survival outcome equivalent to mastectomy [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

Montazeri Aliabadi,

Manda,

Sidgal

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Breast cancer became the most diagnosed cancer in the world in 2020. Chemotherapy is still the leading clinical strategy in breast cancer treatment, followed by hormone therapy (mostly used in hormone receptor-positive types). However, with our ever-expanding knowledge of signaling pathways in cancer biology, new molecular targets are identified for potential novel molecularly targeted drugs in breast cancer treatment. While this has resulted in the approval of a few molecularly targeted drugs by the FDA (including drugs targeting immune checkpoints), a wide array of signaling pathways seem to be still underexplored. Also, while combinatorial treatments have become common practice in clinics, the majority of these approaches seem to combine molecularly targeted drugs with chemotherapeutic agents. In this manuscript, we start by analyzing the list of FDA-approved molecularly targeted drugs for breast cancer to evaluate where molecular targeting stands in breast cancer treatment today. We will then provide an overview of other options currently under clinical trial or being investigated in pre-clinical studies.

show abstract

Advances in Radiotherapy for Breast Cancer

Cited by 5 publications

References 110 publications

New Approaches in Breast Cancer Radiotherapy

New Approaches in Breast Cancer Radiotherapy

The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories

Contact Info

Product

Resources

About